JP7437646B2 - ピロロ［２，３－ｄ］ピリミジン化合物のための製造方法および中間体ならびにその使用 - Google Patents

ピロロ［２，３－ｄ］ピリミジン化合物のための製造方法および中間体ならびにその使用 Download PDF

Info

Publication number
JP7437646B2
JP7437646B2 JP2019124976A JP2019124976A JP7437646B2 JP 7437646 B2 JP7437646 B2 JP 7437646B2 JP 2019124976 A JP2019124976 A JP 2019124976A JP 2019124976 A JP2019124976 A JP 2019124976A JP 7437646 B2 JP7437646 B2 JP 7437646B2
Authority
JP
Japan
Prior art keywords
pyrrolo
amino
methyl
pyrimidin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019124976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020007308A5 (enExample
JP2020007308A (ja
Inventor
カシュミリラル アローラ カピルデヴ
コール デフォレスト ジェイコブ
ケヴィン ヒルズ アンドリュー
パトリック ジョーンズ ブライアン
ニコル ジョーンズ クリス
アーサー ルイス チャド
マハデオ レニ アニール
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2020007308A publication Critical patent/JP2020007308A/ja
Publication of JP2020007308A5 publication Critical patent/JP2020007308A5/ja
Application granted granted Critical
Publication of JP7437646B2 publication Critical patent/JP7437646B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2019124976A 2018-07-06 2019-07-04 ピロロ［２，３－ｄ］ピリミジン化合物のための製造方法および中間体ならびにその使用 Active JP7437646B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862694698P 2018-07-06 2018-07-06
US62/694698 2018-07-06
US201862776642P 2018-12-07 2018-12-07
US62/776642 2018-12-07
US201962855071P 2019-05-31 2019-05-31
US62/855071 2019-05-31

Publications (3)

Publication Number Publication Date
JP2020007308A JP2020007308A (ja) 2020-01-16
JP2020007308A5 JP2020007308A5 (enExample) 2022-07-11
JP7437646B2 true JP7437646B2 (ja) 2024-02-26

Family

ID=67928862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019124976A Active JP7437646B2 (ja) 2018-07-06 2019-07-04 ピロロ［２，３－ｄ］ピリミジン化合物のための製造方法および中間体ならびにその使用

Country Status (14)

Country Link
US (3) US10815240B2 (enExample)
EP (1) EP3817810B1 (enExample)
JP (1) JP7437646B2 (enExample)
KR (1) KR102568464B1 (enExample)
CN (1) CN112384282B (enExample)
AU (1) AU2019299666B2 (enExample)
BR (1) BR112020025701A2 (enExample)
CA (1) CA3105161C (enExample)
ES (1) ES3045115T3 (enExample)
IL (1) IL279926B2 (enExample)
MX (2) MX2020013896A (enExample)
TW (1) TWI709562B (enExample)
WO (1) WO2020008391A1 (enExample)
ZA (1) ZA202100196B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232470A1 (en) 2019-05-13 2020-11-19 Boragen, Inc. Chemical compounds
CN113637018A (zh) 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 磺酰胺类化合物的晶型及其制备方法
CN112279785B (zh) * 2020-10-29 2022-08-16 苏利制药科技江阴有限公司 3,3-二氟环丁胺盐酸盐中间体及其合成方法和3,3-二氟环丁胺盐酸盐合成方法
CN113583992B (zh) * 2021-07-15 2023-06-27 华东理工大学 一种还原胺化酶及其在仲胺合成中的应用
US20240383893A1 (en) * 2021-09-10 2024-11-21 Haihe Biopharma Co., Ltd. Hydroxamic Acid Compound Having ENPP1 Inhibitory Activity and Use Thereof
ES2993658B2 (es) 2023-06-27 2025-07-02 Moehs Iberica Sl (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
ES3040374A1 (es) 2024-04-30 2025-10-30 Moehs Iberica Sl Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000128867A (ja) 1998-10-26 2000-05-09 Ube Ind Ltd １−スルホニルピラゾール誘導体及びその製造方法
JP2003005323A (ja) 2001-06-20 2003-01-08 Konica Corp 熱現像写真感光材料及び画像形成方法
JP2010529002A (ja) 2007-06-01 2010-08-26 グラクソ グループ リミテッド ピロロピリジン化合物、その調製方法、および医薬としてのその使用
JP2014523892A (ja) 2011-07-08 2014-09-18 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト チエタンアミンの製造方法
JP2016509049A (ja) 2013-02-22 2016-03-24 ファイザー・インク ヤヌス関連キナーゼ（ＪＡＫ）の阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
JP2017524007A (ja) 2014-08-12 2017-08-24 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CN102471248B (zh) * 2009-08-10 2015-01-07 Bhi有限合伙公司 用于递送1,3-丙二磺酸的方法、化合物和组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000128867A (ja) 1998-10-26 2000-05-09 Ube Ind Ltd １−スルホニルピラゾール誘導体及びその製造方法
JP2003005323A (ja) 2001-06-20 2003-01-08 Konica Corp 熱現像写真感光材料及び画像形成方法
JP2010529002A (ja) 2007-06-01 2010-08-26 グラクソ グループ リミテッド ピロロピリジン化合物、その調製方法、および医薬としてのその使用
JP2014523892A (ja) 2011-07-08 2014-09-18 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト チエタンアミンの製造方法
JP2016509049A (ja) 2013-02-22 2016-03-24 ファイザー・インク ヤヌス関連キナーゼ（ＪＡＫ）の阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
JP2017524007A (ja) 2014-08-12 2017-08-24 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry，2018年，61(3)，p.1130-1152
MERCK INDEX 13th Edition，2001年，p.ONR-63
RN 1006517-41-4 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2008年03月04日，検索日：05 JUL 2023
RN 885434-77-5 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2006年05月24日，検索日：05 JUL 2023
RN 885440-08-4 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2006年05月24日，検索日：05 JUL 2023
RN 902708-70-7 REGISTRY，DATABASE REGISTRY [ONLINE] Retrieved from STN，2006年08月18日，検索日：05 JUL 2023
平山令明編，有機化合物結晶作製ハンドブック －原理とノウハウ－，丸善株式会社，2008年07月25日，p.57-84
芦澤一英，医薬品の多形現象と晶析の化学，2002年，p.273,278,305-17

Also Published As

Publication number Publication date
MX2023006842A (es) 2023-06-22
US20220127274A1 (en) 2022-04-28
IL279926A (en) 2021-03-01
TW202017929A (zh) 2020-05-16
TWI709562B (zh) 2020-11-11
CN112384282A (zh) 2021-02-19
EP3817810A1 (en) 2021-05-12
WO2020008391A1 (en) 2020-01-09
CN112384282B (zh) 2024-07-02
US10815240B2 (en) 2020-10-27
CA3105161A1 (en) 2020-01-09
US20210009601A1 (en) 2021-01-14
JP2020007308A (ja) 2020-01-16
IL279926B1 (en) 2023-08-01
AU2019299666A1 (en) 2021-01-07
US11254684B2 (en) 2022-02-22
MX2020013896A (es) 2021-03-09
US20200123159A1 (en) 2020-04-23
ES3045115T3 (en) 2025-11-27
EP3817810B1 (en) 2025-09-17
AU2019299666B2 (en) 2024-07-11
US12018031B2 (en) 2024-06-25
ZA202100196B (en) 2022-09-28
CA3105161C (en) 2022-11-15
IL279926B2 (en) 2023-12-01
BR112020025701A2 (pt) 2021-03-16
KR102568464B1 (ko) 2023-08-21
EP3817810C0 (en) 2025-09-17
KR20210029234A (ko) 2021-03-15

Similar Documents

Publication Publication Date Title
JP7437646B2 (ja) ピロロ［２，３－ｄ］ピリミジン化合物のための製造方法および中間体ならびにその使用
US20250282789A1 (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
RU2780482C2 (ru) СПОСОБ ПОЛУЧЕНИЯ И ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ПОЛУЧЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА И ЕГО ПРИМЕНЕНИЕ
RU2803145C2 (ru) Кристаллический пиримидинил-3,8-диазабицикло[3.2.1]октанилметанон и его применение
US12410172B2 (en) Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
HK40047992A (en) Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
HK40047992B (zh) 吡咯并[2 ,3-d]嘧啶化合物的制造方法与中间体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240131

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240201

R150 Certificate of patent or registration of utility model

Ref document number: 7437646

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150